Abstract
One of the most exciting recent developments in neuroscience has been the discovery that classical neurotransmitters are not the only information-carrying substances in the central nervous system (CNS). More than fifty peptide neurotransmitter or neuromodulatory substances including substance P, cholecystokinin, the enkephalins, and neurotensin (NT) have been observed to interact with and modify the activity of dopamine (DA) neurons. The interaction between the endogenous, tridecapeptide NT, and the classical catecholamine, neurotransmitter, DA, has been of particular interest, as these two systems may be integrally involved in the pathogenesis of certain neuropsychiatric disorders, e.g. schizophrenia, as well as in the mechanism of action of antipsychotic drugs. Since the isolation and characterization of NT by Carraway and Leeman (1973), considerable progress has been made towards elucidating the role of this neuropeptide in the regulation of DA neuronal activity (for extensive review see: Nemeroff, 1986). This chapter focuses on interactions of NT and DA in the CNS, with emphasis on the effects of centrally administered NT, as well as the clinical implications of this interaction. Recent findings from this and other laboratories are highlighted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andrade, R., Aghajanian, G.K. (1981). Neurotensin selectively activates dopamine neurons in the substantia nigra. Soc. Neurosci. Abstr., 7, 573.
Bentall, A.C.C, Herberg, L.J. (1980). Blockade of amphetamine-induced locomotor activity and stereotypy in rats by spiroperidol but not by an atypical neuroleptic thioridazine. Neuropharmacology, 19, 699–703.
Bissette, G., Jennes, L., Prange, Jr., A.J., Breese, G.R., Nemeroff, C.B. (1983). Neurotensin and dopamine are not co-localized in rat brain. Soc. Neurosci. Abstr., 9, 290.
Bissette, G., Nemeroff, C.B., Decker, M.W., Kizer, J.S., Agid, Y., Javoy-Agid, F. (1985). Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson’s disease. Ann. Neurol., 17, 324–329.
Bissette, G., Dauer, W.T., Kilts, C.D., O’Connor, L., Nemeroff, C.B. (1986). Effect of d-amphetamine and dopamine receptor antagonists on neurotensin concentrations in microdissected rat brain regions. Soc. Neurosci. Abstr., 12, 33.
Cain, S.T., Nemeroff, C.B. (1985). Hypolocomotion induced by activation of dopamine autoreceptors effects of neurotensin. Soc. Neurosci. Abstr., 11, 340.
Carraway, R., Leeman, S.E. (1973). The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem., 248, 6854–6861.
Costall, B., Naylor, R.J. (1976). A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride, and metaclopramide to antagonize the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Eur. J. Pharmacol., 40, 9–19.
Dupont, A., Merand, Y. (1978). Enzyme inactivation of neurotensin by hypothalamic and brain extracts of the rat. Life Sci., 22, 1623–1630.
Emson, P.C., Goedert, M., Horsfield, P.M., Rioux, F., St. Pierre, S. (1982). The regional distribution and chromatographic characterization of neurotensin-like immunoreactivity in the rat central nervous system. J. Neurochem., 28, 992–999.
Ervin, G.N., Nemeroff, C.B. (1987). Intra-accumbens injection of neurotensin antagonizes the behavioral supersensitivity to L-DOPA in dopamine denervated rats. Ann. NY Acad. Sci., (in press).
Ervin, G.N., Birkemo, L.S., Nemeroff, C.B., Prange, Jr., A.J. (1981). Neurotensin blocks certain amphetamine behaviors. Nature, 291, 73–76.
Garcia-Sevilla, J.A., Magnusson, T., Carlsson, A., Leban, J., Folkers, K. (1978). Neurotensin and its amide analogue [Gln4]-neurotensin: effects on brain monoamine turnover. NS Arch. Pharmacol., 305, 213–218.
Glimcher, P.W., Giovino, A.A., Hoebel, B.G. (1987). Neurotensin self-injection in the ventral tegmental area. Brain Res., 403, 147–150.
Govoni, S., Hong, J.S., Yang, H-Y.T., Costa, E. (1980). Increase of neurotensin content elicited by neuroleptics in nucleus. accumbens. J. Pharmacol. Exp. Ther. 215, 413–417.
Griffiths, E.C., Slater, P., Webster, V.A.D. (1981). Behavioural interactions between neurotensin and thyrotropin releasing hormone in rat central nervous system. J. Physiol., 320, 90.
Hokfelt, T., Everitt, B.J., Theodorsson-Norheim, E., Goldstein, M. (1984). Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol., 222, 543–559.
Ibata, Y., Okamura, F.H, Kawakami, T., Tanaka, M., Obata, H.L., Tsuto, O.T, Terubayashi, H., Yanaihara, C., Yanaihara, N. (1983). Coexistence of dopamine and neurotensin in hypothalamic arcuate and periventricular neurons. Brain Res., 269, 177–179.
Iversen, L.L., Iversen, S.D., Bloom, F., Douglas, C., Brown, M., Vale, W. (1978). Calcium-dependent release of somatostatin and neurotensin from rat brain invitro. Nature, 273, 161.
Kalivas, P.W., Nemeroff, C.B., Prange, Jr., A.J. (1982). Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin. Eur. J. Pharmacol., 78, 471–474.
Kalivas, P.W., Nemeroff, C.B., Prange, Jr., A.J. (1984). Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience, 11, 919–930.
Kilts, C.D., Anderson, C.M., Bissette, C., Ely, T.D., Nemeroff, C.B. (1987). Differential effects of antipsychotic drugs on the neurotensin content of discrete rat brain nuclei. Biochem. Pharmacol., (in press).
Kitabgi, P., Carraway, R., Van Rietschoten, J., Granier, C., Morgat, J.L., Mendez, A., Leeman, S., Freychet, P. (1977). Neurotensin: specific binding to synaptic membranes from rat brain. Proc. Natl. Acad. Sci. USA, 74, 1846–1850.
Levant, B., Nemeroff, C.B. (1987). The psychobiology of neurotensin. In: The Neuroendocrinology of Mood (K. Fuxe, D. Ganten, D. Pfaff Eds.). Springer Verlag, Berlin-Heidelberg-New York, (in press).
Levant, B., Bissette, G., Parker, Y-M., Nemeroff, C.B. (1987). Alterations in neurotensin and bombesin-like immunoreactivity in MPTP-treated mice. Ann. NY Acad. Sci., (in press).
Luttinger, D., King, R.A., Sheppard, D., Strupp, J., Nemeroff, C.B., Prange, Jr., A.J. (1982a). The effect of neurotensin on food consumption in the rat. Eur. J. Pharmacol., 81, 499–504.
Luttinger, D., Nemeroff, C.B., Prange, Jr., A.J. (1982b). The effects of neuropeptides on discrete-trial conditioned avoidance responding. Brain Res., 237, 183–192.
Nemeroff, C.B. (1986). The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology, 11, 15–37.
Nemeroff, C.B., Hernandez, D.E., Luttinger, D., Kalivas, P., Prange, Jr., A.J. (1982). Interactions of neurotensin with brain dopamine systems. Ann. NY Acad. Sci., 400, 330–344.
Nemeroff, C.B., Luttinger, D., Hernandez, D.E., Mailman, R.B., Mason, G.A., Davis, S.D., Widerlov, E., Frye, G.D., Kilts, C.D., Beaumont, K. Breese, G.R., Prange, Jr., A.J. (1983a). Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther., 225, 337–345.
Nemeroff, C.B., Youngblood, W., Manberg, P.J., Prange, Jr., A.J., Kizer, J.S. (1983b). Regional brain concentrations of neuropeptides in Huntington’s chorea and schizophrenia. Science, 221, 972–975.
Palacios, J.M., Kuhar, M.J. (1981). Neurotensin receptors are located on dopamine-containing neurons in rat midbrain. Nature, 294, 587–589.
Quirion, R., Everist, H.D., Pert, A. (1982). Nigrostriatal dopamine terminals bear neurotensin receptors but the mesolimbic do not. Soc. Neurosci. Abstr., 8, 582.
Sadoul, J-L., Checler, F., Kitabgi, P., Rostrene, W., Javoy-Agid, F., Vincent, J-P. (1984). Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. Biochem. Biophys. Res. Commun., 125, 395–404.
Skoog, K.M., Cain, S.T., Nemeroff, C.B. (1986). Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine. Neuropharmacology, 25, 777–782.
Uhl, G.R., Kuhar, M.J. (1984). Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature, 309, 350–352.
Uhl, G.R., Snyder, S.H. (1977). Regional and subcellular distribution of brain neurotensin. Life Sci., 19, 1827–1832.
Uhl, G.R., Whitehouse, P.J., Price, D.L., Tourtelotte, W.W., Kuhar, M.J. (1984). Parkinson’s disease: depletion of substantia nigra neurotensin receptors. Brain Res., 308, 186–190.
van Wimersma Greidanus, T.B., van Praag, M.C.G., Kalmann, R., Rinkel, G.J.E., Croiset, G., Hoeke, E.C., van Egmond, M.A.H., Fekete, M. (1982). Behavioral effects of neurotensin. Ann. NY Acad. Sci., 400, 319–329.
Widerlov, E., Kilts, C.D., Mailman, R.B., Nemeroff, C.B., McCown, T.J., Prange, Jr., A.J., Breese, G.R. (1982a). Increase in dopamine metabolites in rat brain by neurotensin. J. Pharmacol. Exp. Ther., 222, 1–6.
Widerlov, E., Lindstrom, L.H., Besev, G., Manberg, P.J., Nemeroff, C.B., Breese, G.R., Kizer, J.S., Prange, Jr., A.J. (1982b). Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am. J. Psychiatry, 139, 1122–1126.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1988 Beth Levant, Garth Bissette and Charles B. Nemeroff
About this chapter
Cite this chapter
Levant, B., Bissette, G., Nemeroff, C.B. (1988). Further Evidence for Neurotensin-Dopamine Interactions in the Central Nervous System. In: Beart, P.M., Woodruff, G.N., Jackson, D.M. (eds) Pharmacology and Functional Regulation of Dopaminergic Neurons. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-10047-7_45
Download citation
DOI: https://doi.org/10.1007/978-1-349-10047-7_45
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-10049-1
Online ISBN: 978-1-349-10047-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)